” …significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment.”
Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms.
RESULTS:
In both groups there was a significant reduction in the Kupperman index following 12 weeks of treatment, which was sustained throughout the 12 months of treatment (p < 0.01). Seventy-six percent of the patients in the SD group reported a decrease in vasomotor symptoms and seventy-eight % in the LD group (NS). This decrease was sustained following 12 months of treatment. There was no change in TSH and sex hormone levels or endometrial thickness during the study period.